2,4,5-Trifluorobenzyl Bromide CAS 157911-56-3 Purity >98.0% (GC) Ensitrelvir (S-217622) Intermediate COVID-19

Short Description:

Chemical Name: 2,4,5-Trifluorobenzyl Bromide

CAS: 157911-56-3

Purity: >98.0% (GC)

Appearance: Colorless to Light Yellow Clear Liquid

Intermediate of Ensitrelvir (S-217622), COVID-19

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Commercial Supply Ensitrelvir (S-217622) Intermediates:
S-Ethylisothiourea Hydrobromide CAS 1071-37-0
2,4,5-Trifluorobenzyl Bromide CAS 157911-56-3
Trimethyloxonium Tetrafluoroborate CAS 420-37-1
6-Chloro-2-methyl-2H-indazol-5-amine CAS 1893125-36-4
3-(Chloromethyl)-1-methyl-1H-1,2,4-triazole hydrochloride CAS 135206-76-7
1,3,5-Triazine-2,4(1H,3H)-dione, 3-(1,1-dimethylethyl)-6-(ethylthio)- CAS 1360105-53-8

Chemical Properties:

Chemical Name	2,4,5-Trifluorobenzyl Bromide
Synonyms	1-(Bromomethyl)-2,4,5-trifluorobenzene
CAS Number	157911-56-3
CAT Number	RF-PI1505
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C7H4BrF3
Molecular Weight	225.01
Flash Point	75℃
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	Colorless to Light Yellow Clear Liquid
Purity / Analysis Method	>98.0% (GC)
Moisture (K.F)	≤0.50%
Specific Gravity (20/20)	1.714~1.719
Refractive Index (N20/D)	1.505~1.509
Total Impurities	<2.00%
Infrared Spectrum	Conforms to Structure
Test Standard	Enterprise Standard
Usage	Pharmaceutical Intermediates

Package & Storage:

Package: Bottle, 25kg/Barrel, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.

Advantages:

FAQ:

Application:

2,4,5-Trifluorobenzyl Bromide (CAS: 157911-56-3) is mainly used in pharmaceutical industry as a pharmaceutical intermediate. 2,4,5-Trifluorobenzyl Bromide is an important intermediate in the synthesis of Sitagliptin (CAS: 486460-32-6). 2,4,5-Trifluorobenzyl Bromide is also an important intermediate of Ensitrelvir (S-217622). Ensitrelvir, a therapeutic drug for COVID-19, is a 3CL protease inhibitor created through joint research between Hokkaido University and Shionogi. SARS-CoV-2 has an enzyme called 3CL protease, which is essential for the replication of the virus. Ensitrelvir suppresses the replication of SARS-CoV-2 by selectively inhibiting 3CL protease.